Ignite Creation Date:
2024-05-05 @ 4:46 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00311649
Status:
COMPLETED
Last Update Posted:
2011-08-12
First Post:
2006-04-05
Brief Title:
Open Label Evaluation of H5N1 Vaccine at Vaccine Manufacturing Facilities
Sponsor:
National Institute of Allergy and Infectious Diseases NIAID
Organization:
National Institute of Allergy and Infectious Diseases NIAID
Study Overview
Official Title:
Open Label Evaluation of H5N1 Vaccine at Vaccine Manufacturing Facilities
Status:
COMPLETED
Status Verified Date:
2007-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this research is to study side effects and safety of a new H5N1 flu bird flu vaccine and to look at how well peoples immune systems make antibodies to fight infection after they get the vaccine Up to 300 healthy people who are working at Aventis Pasteur H5N1 virus vaccine production facility in Swiftwater PA during the flu season are being asked to participate It is important for vaccine production workers to receive the vaccine in order to minimize the risk of this bird flu virus combining with the regular flu virus Volunteers in this study will have a medical screening 2 vaccinations a month apart 2 blood sample collections 1 before and 1 after the vaccinations to compare 5 clinic visits and follow-up over 6 months They will also complete a diary card and to write down their temperature once a day and any symptoms they have every day during the week after they get their second shot They will also be asked to write down any drugs or medicines they take
Detailed Description:
The primary goal of this phase III single center open label study is to obtain additional safety and immunogenicity data on two 90 µg doses of H5N1 It is anticipated that this dose level will result in an acceptable proportion of subjects achieving a potentially protective postvaccination antibody titer combined with an acceptable safety profile The purpose of the current study is to induce maximal anti-H5N1 titers as quickly as possible in order to protect at-risk personnel manufacturing a commercial-scale H5N1 vaccine under contract to the United States government The study will be performed under the direction of investigators at the University of Maryland School of Medicines Center for Vaccine Development Volunteers will be enrolled vaccinated and followed at Sanofi Pasteur in Swiftwater PA Up to 300 healthy vaccine production worker volunteers aged 18 years and older will receive 90 mcg of the influenza AH5N1 vaccine by intramuscular injection Volunteers will receive 2 doses of the vaccine separated by approximately 28 days Serum HAI and neutralizing antibody titers will be assessed approximately 1 month after the second vaccine dose Volunteers will be observed in the clinic for at least 15 minutes after each vaccination and they will maintain a memory aid to record oral temperature and systemic and local adverse events AEs for seven days after each immunization Volunteers will return to the clinic on Day 7 for AE and concomitant medication assessment a targeted physical examination if indicated and review of the memory aid Serum for immunogenicity evaluations will be obtained prior to the first vaccination Day 0 and on Day 56 Primary study objectives are to 1 determine the safety of subvirion inactivated AH5N1 vaccine in healthy vaccine production workers adults and 2 determine the immunogenicity of subvirion inactivated H5N1 vaccine in healthy adults approximately 1 month following receipt of two 90 mcg doses of vaccine Primary study endpoints are 1 adverse event AE or serious adverse event information solicited in-clinic and via memory aids concomitant medications and periodic targeted physical assessment 2 geometric mean titer GMT and frequency of 4-fold or greater increases in neutralizing antibody titers at two months after receipt of the first dose of vaccine 3 GMT and frequency of 4-fold or greater increases in serum hemagglutination inhibition HAI antibody titers at 2 months after receipt of the first dose of vaccine and 4 proportion of subjects achieving a serum neutralizing antibody titer of 140 against the influenza AH5N1 virus 28 days after receipt of the second dose of vaccine approximately Day 56
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| Influenza CVD 16000 | None | None | None |